Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To explore whether varenicline (Chantix) showed more efficacy in treating certain subgroups of patients. In a recent multisite trial, varenicline was shown to be effective in reducing drinking in alcohol-dependent patients, both smokers and nonsmokers. Given the heterogeneity among alcohol-dependent patients, secondary analyses were conducted to determine whether certain subgroups responded more favorably than others to treatment with varenicline. METHODS: Data were drawn from a phase 2 randomized, double-blind, placebo-controlled multisite 13-week trial of varenicline in alcohol-dependent patients (Litten et al., 2013). Seventeen moderator variables were selected for exploratory testing on the basis of theoretical and scientific interest. RESULTS: Of the 17 moderator variables assessed, 4 were statistically significant, including cigarettes per day reduction, treatment drinking goal, years drinking regularly, and age of the patient. Two other variables—the type of adverse events experienced by patients and the severity of alcohol-related consequences—seemed to moderate the varenicline treatment effect at borderline statistical significance. Individuals who reduced the number of cigarettes per day experienced a significant effect from varenicline in reducing drinking, whereas those who did not change or who increased their number of cigarettes observed no beneficial effect. Reviewing the moderators related to severity, varenicline seemed to have greater efficacy than placebo among less severely dependent patients. CONCLUSIONS: Varenicline seems to be more efficacious in certain subgroups, particularly in those who reduced their smoking and in the "less severe" patient. Additional studies are warranted to confirm the results of these exploratory analyses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · cited 1×
“Therefore, up to 4 statistically significant interaction tests could occur by chance alone (Wang et al., 2007).”
BackgroundGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 1×
“The stratification variables were clinical site and regular smoking (≥10 cigarettes vs 10 cigarettes smoked per day for the past week) (Gonzales et al., 2006).”
Psychometric properties of the Penn Alcohol Craving Scale
Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04349.x · Cited by 852 · cited 2×
“These included 14 baseline characteristics: (1) gender, (2) age, (3) years of drinking regularly, (4) parental problem drinking, (5) treatment drinking goal, (6) DPD during 28 days pre-screening and (7) DPD during 7 days pre-randomization, (8) pre-randomization reducer in DPD, (9) number of alcohol dependence criteria…”
Recovery from DSM‐IV alcohol dependence: United States, 2001–2002
Dawson, D. A., Grant, B. F., Stinson, F. S., Chou, P. S., Huang, B., & Ruan, W. J. (2005) · Addiction · doi:10.1111/j.1360-0443.2004.00964.x · Cited by 597
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Addiction is a Reward Deficit and Stress Surfeit Disorder
Koob, G. F. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00072 · Cited by 397
Litten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 21×
“Treatment goal and PACS were included as covariates because they were correlated with drinking outcome and because they were used covariates in the models presented in our main article (Litten et al., 2013).”
InfluentialSelf-citationGrady, S. R., Drenan, R. M., Breining, S. R., Yohannes, D., Wageman, C. R., Fedorov, N. B., McKinney, S., Whiteaker, P., Bencherif, M., Lester, H. A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.01.013 · Cited by 98 · cited 1×
“Varenicline is a partial agonist at the α4β2-nicotinic receptor, and although it exhibits to a lesser degree, it is a partial agonist at the α3β2- and α6β2receptors and a full agonist at the α7- and α3β4-nicotinic receptors (Mihalak et al., 2006; Grady et al., 2010).”
Cited by
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Self-citationNovel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Moderator analyses of data collected in the above multisite trial [142] indicated that varenicline was more efficacious in reducing drinking among smokers who also reduced their cigarette smoking [147] and among individuals with lower severity of AUD, such that that varenicline significantly reduced percent heavy-drin…”
BackgroundRoche, D. J. O., Bujarski, S., Green, R., Hartwell, E. E., Leventhal, A. M., & Ray, L. A. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.035 · Cited by 106
Aranäs, C., Blid Sköldheden, S., & Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180512 · Cited by 20
“Moreover, as human studies reveal effects of varenicline in smokers with AUD (McKee et al., Mitchell et al., 2012; Litten et al., 2013; Roberts et al., 2017b; Roberts et al., 2017a; Falk et al., 2015; de Bejczy et al., 2015; Verplaetse et al., 2016), the possibility that varenicline reduces alcohol drinking in nicotin…”
Background
Metadata
- Authors
- Falk, D. E., Castle, I.-J. P., Ryan, M., Fertig, J., & Litten, R. Z.
- Venue
- Journal of Addiction Medicine
- Published
- 2015-07
- Volume
- 9
- Issue
- 4
- Pages
- 296-303
- ISSN
- 1932-0620 (ISSN-L)
- OpenAlex
- W2417560069
- Cited by
- 59
- References
- 8
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis. https://app.cochat.ai/papers/10.1097/adm.0000000000000133
- The paper
- Falk, D. E., Castle, I.-J. P., Ryan, M., Fertig, J., & Litten, R. Z. (2015). Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.